Dr. Larrick’s main focus is protein therapeutics, but his research breadth covers a diverse range of scientific disciplines to create novel therapeutic candidates. His is a leading expert in the research of: sepsis, innate and adaptive immunity, antibody therapeutics, antibody humanization, biology of human aging,
Dr. James Larrick is a biomedical entrepreneur with an international reputation in biotechnology [cytokines, therapeutic antibodies, molecular biology, pharmaceutical drug development] having written or co-authored eight books, over 250 papers/chapters and >forty patents in his twenty-five year career. He has served on the editorial board of six journals. Dr. Larrick’s work on therapeutic antibodies and other protein therapeutics has spanned the whole range of biopharmaceutical product development from target discovery, process science to clinical trials. Dr. Larrick received his MD and PhD. degrees from Duke University School of Medicine. He trained at Stanford and was then a founding scientist at Cetus Immune where he became Director of Research. In 1992, Dr. Larrick founded the non-profit Panorama Institute of Molecular Medicine, and Panorama Research Inc., a biotech incubator. Dr. Larrick’s team has discovered developed a diverse, and innovative portfolio of pharmaceutical molecules addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated >20 life science companies,. including Kalobios, Absalus Inc. (now Teva Inc.), Galaxy Biotech, and TransTarget Inc. Dr. Larrick has been a member of angel groups and serves as a managing director and Chief Medical Officer of Velocity Pharmaceutical Development LLC in S. San Francisco.
BA, chemistry, Colorado College
MD, PhD, membrane chemistry, Duke University Medical School
Select list from over 250 papers.
- Mendelsohn AR, Larrick JW. 2014. Partial reversal of skeletal muscle aging by restoration of normal NAD+ levels. Rejuvenation Res. Jan 13. [Epub ahead of print]
- Mendelsohn AR Larrick JW. 2013. Medical implications of basic research in aging. 1st edition. Palo Alto, CA: Eosynth Press.
- Larrick JW, Mendelsohn A, Sharma V, Wang J, Fang J, Huang M, Wages JM, Wright SC. 2013. Trophokines: novel therapy for senescence-related fibrosis. Chapter 28 in: Inflammation, Advancing Age and Nutrition: Research and Clinical Interventions. Eds., Rahman I, Bagchi D. Elsevier/Academic Press.
- Mendelsohn AR, Larrick JW. 2013. Sleep facilitates clearance of metabolites from the brain: glymphatic function in aging and neurodegenerative diseases. Rejuvenation Res. 16:518-23
- Mendelsohn AR, Larrick JW.2013. Trade-offs between anti-aging dietary supplementation and exercise. Rejuvenation Res. 16:419-26
- Mendelsohn AR, Larrick JW.2013. Rejuvenation of aging hearts. Rejuvenation Res. 16:330-2
- Mendelsohn AR, Larrick JW.2013. Rejuvenation of adult stem cells: is age-associated dysfunction epigenetic? Rejuvenation Res. 16:241-4
- Mendelsohn AR, Larrick JW.2013. Rejuvenation of adult stem cells: is age-associated dysfunction epigenetic? Rejuvenation Res. 16:152-7
- Mendelsohn AR, Larrick JW. 2013. The DNA methylome as a biomarker for epigenetic instability and human aging. Rejuvenation Res. 16:74-7
- 1.Larrick JW. 2012. Progress with promising human antibodies. Immunotherapy 4:1-5.
- Mendelsohn AR, Larrick JW. 2012. Fibroblast growth factor-21 is a promising dietary restriction mimetic. Rejuvenation Res. 15:624-8
- Lamdan H, Gavilondo JV, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Ayala M, Rojas G, Balint RF, Larrick JW. 2013. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor. Mol Biosyst. 9:2097-106
- Mendelsohn AR, Larrick JW. 2012. Dietary restriction: critical co-factors to separate health span from life span benefits. Rejuvenation Res. 15:523-9
- Mendelsohn AR, Larrick JW. 2012. Ectopic expression of telomerase safely increases health span and life span. Rejuvenation Res. 15:435-8
- Mendelsohn AR, Larrick JW. 2012. Dissecting mammalian target of rapamycin to promote longevity. Rejuvenation Res. 15:334-7
- Mendelsohn AR, Larrick JW. 2012. Epigenetic-mediated decline in synaptic plasticity during aging. Rejuvenation Res. 15:98-101
- Mendelsohn AR, Larrick JW. 2011. Overcoming the aging systemic milieu to restore neural stem cell function. Rejuvenation Res. 14:681-4
- Mendelsohn AR, Larrick JW. 2011. Reversing age-related decline in working memory. Rejuvenation Res. 14:557-9
- Mendelsohn AR, Larrick JW. 2011. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases. Rejuvenation Res. 14:437-41
- Mendelsohn AR, Larrick JW. 2011. Medical implications of basic science: protein homeostasis as a clinical target for increased longevity? Rejuvenation Res. 14:335-9
- Mendelsohn AR, Larrick JW. 2011. Master switch of mitochondrial biogenesis: a clinical target for health span enhancement? 14:223-6
- Mendelsohn AR, Larrick JW. 2010. Applied Healthspan engineering. Rejuvenation Res. 13:265-80
- Chan CK, Liao S, Li B, Lareu RR, Larrick JW, Ramakrishna S, Raghunath M. 2009. Early adhesive behavior of bone-marrow-derived mesenchymal stem cells on collagen electrospun fibers. Biomed Mater 4:350-6.
- Wang Y, Jiang J, Jiang X, Cai S, Han H, Li L, Tian Z, Jiang W, Zhang Z, Xiao Y, Wright SC, Larrick JW. 2008. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog. Bioorg Med Chem 16:6552-9.
- Lee RJ, Fang Q, Davol, PA, Gu Y, Sievers RE, Grabert RC, Gall, JM, Yee MS, Fok,H, Huang NF, Padbury JF, Larrick JW, Lum JG. 2007. Antibody Targeting of Stem Cells to Infarcted Myocardium. Stem Cells 25:712-7